The CREDENCE trial, a comparative study of the efficacy and safety of canagliflozin versus placebo, has been concluded on the basis of a planned interim data analysis. CREDENCE was a randomized, double-blind, placebo controlled study involving multiple clinical centers. It enrolled about 4400 patients with T2D, with estimated glomerular filtration rate (eFGR) ≥30 to <90 mL/min/1.73 m2, and albuminuria.
Bakris GL. Presented at ISN World Congress of Nephrology 2019.